Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147671 | 0.85 | RET (0.46) | HRH3DYRK1AMEN1KMT2ACYP3A4 | |
| SCHEMBL20147664 | 0.85 | RET (0.45) | HRH3DYRK1AMEN1KMT2ACYP3A4 | |
| SCHEMBL20068949 | 0.84 | SSTR4 (0.51) | MEN1KMT2AKDM5AMAPK8MAPK10 | |
| SCHEMBL20147666 | 0.83 | RET (0.47) | HRH3DYRK1ACYP3A4CYP2D6HTR4 | |
| SCHEMBL20152070 | 0.82 | MEN1 (0.47) | DYRK1AMEN1KMT2AKDM5AWNT1 | |
| SCHEMBL20147919 | 0.81 | HTR4 (0.45) | HTR4F10 | |
| SCHEMBL14291279 | 0.80 | MCHR1 (0.42) | HRH3DYRK1ASLC6A5MEN1KMT2A | |
| SCHEMBL20147997 | 0.77 | RET (0.44) | DYRK1AMEN1KMT2AKDM5AF10 | |
| SCHEMBL22643851 | 0.75 | HRH3 (0.67) | HRH3SLC6A5MEN1KMT2AKDM5A | |
| SCHEMBL10168794 | 0.75 | HRH3 (0.67) | HRH3SLC6A5MEN1KMT2AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HRH3 1000/4885DYRK1A 231/4885SLC6A5 3222/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HRH3 1000/4885DYRK1A 231/4885SLC6A5 3222/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | HRH3 1000/4885DYRK1A 231/4885SLC6A5 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.